

02-06-02

A

# UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.

P50504C1

First Named Inventor

Deen et al.

For new nonprovisional applications under 37 CFR 1.53(b)

**"EXPRESS MAIL CERTIFICATE"**EXPRESS MAIL MAILING LABEL NUMBER EL808219615US DATE OF DEPOSIT: 04 February 2002

By certifying that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service Express Mail Post Office to Addressee service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to: The Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

NAME OF PERSON MAILING PAPER OR FEE

(TYPE OR PRINT)

Elsa Matos

SIGNATURE

Elsa Matos

JC997 U.S. PTO

10/066895

02/04/02

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>	
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570 <input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) <i>(Submit an original, and a duplicate for fee processing)</i>	7. <input checked="" type="checkbox"/> The Title of the Invention: <b>HUMAN MONOCLONAL ANTIBODIES</b>
2. <input checked="" type="checkbox"/> The total fee is calculated as shown below: Basic Filing fee \$740.00 Total Claims 17 - 20 = 0 x \$18 \$ 0.00 Independent Claims 2 - 3 = 0 x \$84 \$ 0.00 <input type="checkbox"/> Multiple Dependent Claim present. \$280 \$ <b>TOTAL FILING FEE \$740.00</b> <input type="checkbox"/> Cancel in this application original claims ___ to ___ of the prior application before calculating the filing fee. <input checked="" type="checkbox"/> Charge <b>\$740.00</b> to the above indicated Deposit Account.	8. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission a. <input type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies d. <input checked="" type="checkbox"/> Use the identical computer-readable form filed in Application No. <u>09/297,344</u> , filed <u>09 June 1999</u> as the computer-readable form for the instant application. (37 CFR 1.821(e))
3a. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] <u>74</u> 3b. <input checked="" type="checkbox"/> Abstract on a separate sheet [Total Pages] <u>1</u>	9. a. <input type="checkbox"/> Information Disclosure Statement (IDS) b. <input checked="" type="checkbox"/> PTO-1449 c. <input type="checkbox"/> Copies of all IDS Citations
4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] <u>31</u>	10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
5. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] <u>3</u> a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17a completed)</i> c. <input type="checkbox"/> Unsigned Declaration <i>[Note Box 6 below]</i> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	11. <input checked="" type="checkbox"/> Prior Application is Assigned to: <b>SmithKline Beecham Corporation</b> <i>(for continuation/divisional with Box 17a completed)</i>
6. <input checked="" type="checkbox"/> Incorporation By Reference <i>(useable if Box 5b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	12. <input checked="" type="checkbox"/> Preliminary Amendment [3 Pages]
	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>
	14. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>
	15. <input checked="" type="checkbox"/> Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. <u>09/297,344</u> filed <u>09 June 1999</u> . A PTO-1449 listing the references is enclosed.
	16. <input type="checkbox"/> Other: _____

17. <input checked="" type="checkbox"/> Priority Information, check appropriate box and supply the requisite information
a. The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: <u>09/297,344</u> filed <u>09 June 1999</u> .
b. <input checked="" type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No: <u>60/030,149</u> filed <u>01 November 1996</u> .
c. <input checked="" type="checkbox"/> Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) This is a continuation of application Serial No. <u>09/297,344</u> filed <u>09 June 1999</u> , which is a §371 of <b>PCT/US97/19203</b> filed <b>23 October 1997</b> .

Correspondence Address:	GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939	Signature Name	Respectfully Submitted, <u>Kirk Baumeister</u> <b>Kirk Baumeister</b>
Telephone	(610) 270-5023 Fax (610) 270-5073	Registration No.	<u>33,833</u>



20462

PATENT TRADEMARK OFFICE